These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23012246)

  • 1. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma.
    Shimura Y; Kuroda J; Ri M; Nagoshi H; Yamamoto-Sugitani M; Kobayashi T; Kiyota M; Nakayama R; Mizutani S; Chinen Y; Sakamoto N; Matsumoto Y; Horiike S; Shiotsu Y; Iida S; Taniwaki M
    Mol Cancer Ther; 2012 Dec; 11(12):2600-9. PubMed ID: 23012246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.
    Matsumura-Kimoto Y; Tsukamoto T; Shimura Y; Chinen Y; Tanba K; Kuwahara-Ota S; Fujibayashi Y; Nishiyama D; Isa R; Yamaguchi J; Kawaji-Kanayama Y; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
    Cancer Med; 2020 Jul; 9(14):5185-5199. PubMed ID: 32420699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
    Zhu YX; Yin H; Bruins LA; Shi CX; Jedlowski P; Aziz M; Sereduk C; Kortuem KM; Schmidt JE; Champion M; Braggio E; Keith Stewart A
    Blood; 2015 Jan; 125(3):483-91. PubMed ID: 25395420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
    Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
    Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of p90 ribosomal S6 kinase potentiates cisplatin activity in A549 human lung adenocarcinoma cells.
    Abdulrahman N; Siveen KS; Joseph JM; Osman A; Yalcin HC; Hasan A; Uddin S; Mraiche F
    J Pharm Pharmacol; 2020 Nov; 72(11):1536-1545. PubMed ID: 32667058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
    Isa R; Horinaka M; Tsukamoto T; Mizuhara K; Fujibayashi Y; Taminishi-Katsuragawa Y; Okamoto H; Yasuda S; Kawaji-Kanayama Y; Matsumura-Kimoto Y; Mizutani S; Shimura Y; Taniwaki M; Sakai T; Kuroda J
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.
    Neise D; Sohn D; Stefanski A; Goto H; Inagaki M; Wesselborg S; Budach W; Stühler K; Jänicke RU
    Cell Death Dis; 2013 Oct; 4(10):e859. PubMed ID: 24136223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study.
    Casalvieri KA; Matheson CJ; Backos DS; Reigan P
    Bioorg Med Chem; 2020 Mar; 28(5):115303. PubMed ID: 31982240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
    Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
    Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.
    Kang S; Dong S; Gu TL; Guo A; Cohen MS; Lonial S; Khoury HJ; Fabbro D; Gilliland DG; Bergsagel PL; Taunton J; Polakiewicz RD; Chen J
    Cancer Cell; 2007 Sep; 12(3):201-14. PubMed ID: 17785202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribosomal S6 kinase 2-forkhead box protein O4 signaling pathway plays an essential role in melanogenesis.
    Jeung D; Lee GE; Chen W; Byun J; Nam SB; Park YM; Lee HS; Kang HC; Lee JY; Kim KD; Hong YS; Lee CJ; Kim DJ; Cho YY
    Sci Rep; 2024 Apr; 14(1):9440. PubMed ID: 38658799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into RSK activation and hematopoietic cancer.
    Cuadrado A; Nebreda AR
    Cancer Cell; 2007 Sep; 12(3):187-9. PubMed ID: 17785199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational and Biochemical Discovery of RSK2 as a Novel Target for Epigallocatechin Gallate (EGCG).
    Chen H; Yao K; Chang X; Shim JH; Kim HG; Malakhova M; Kim DJ; Bode AM; Dong Z
    PLoS One; 2015; 10(6):e0130049. PubMed ID: 26083344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.
    Sapkota GP; Cummings L; Newell FS; Armstrong C; Bain J; Frodin M; Grauert M; Hoffmann M; Schnapp G; Steegmaier M; Cohen P; Alessi DR
    Biochem J; 2007 Jan; 401(1):29-38. PubMed ID: 17040210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Targeting of ERKs/RSK2 Signaling in Cancers.
    Cho YY
    Curr Pharm Des; 2017 Nov; 23(29):4247-4258. PubMed ID: 28714417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.
    Chinen Y; Kuroda J; Shimura Y; Nagoshi H; Kiyota M; Yamamoto-Sugitani M; Mizutani S; Sakamoto N; Ri M; Kawata E; Kobayashi T; Matsumoto Y; Horiike S; Iida S; Taniwaki M
    Cancer Res; 2014 Dec; 74(24):7418-29. PubMed ID: 25269480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CX-F9, a novel RSK2 inhibitor, suppresses cutaneous melanoma cells proliferation and metastasis through regulating autophagy.
    Zhang X; Cai L; Zhao S; Long J; Li J; Wu L; Su J; Zhang J; Tao J; Zhou J; Chen X; Peng C
    Biochem Pharmacol; 2019 Oct; 168():14-25. PubMed ID: 31207212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p90 ribosomal S6 kinase 2 is associated with and dephosphorylated by protein phosphatase 2Cdelta.
    Doehn U; Gammeltoft S; Shen SH; Jensen CJ
    Biochem J; 2004 Sep; 382(Pt 2):425-31. PubMed ID: 15206906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1.
    Frödin M; Jensen CJ; Merienne K; Gammeltoft S
    EMBO J; 2000 Jun; 19(12):2924-34. PubMed ID: 10856237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RSK2-Mediated ELK3 Activation Enhances Cell Transformation and Breast Cancer Cell Growth by Regulation of c-fos Promoter Activity.
    Yoo SM; Lee CJ; An HJ; Lee JY; Lee HS; Kang HC; Cho SJ; Kim SM; Park J; Kim DJ; Cho YY
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.